Foresight Diagnostics’ PhasED-Seq ctDNA assay detects response to acalabrutinib as early as seven days in patients with aggressive B-cell lymphomas

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling